natgillin/translations-raw huggingface dataset:
a Thalidomide dosed once daily at bedtime on Days 1 to 42 of each 42-day cycle. b Due to the sedative effect associated with thalidomide, administration at bedtime is known to generally improve tolerability. c Melphalan dosed once daily on Days 1 to 4 of each 42-day cycle. d Melphalan dosing: reduce by 50% for moderate (creatinine clearance: ≥30 but &lt; 50 mL/min) or severe (CrCl: &lt; 30mL/min) renal insufficiency e Maximum daily melphalan dose: 24 mg (subjects ≤75 years old) or 20 mg (subjects &gt; 75 years old). f Prednisone dosed once daily on Days 1 to 4 of each 42-day cycle.
a Doza talidomida primijenjena jedanput na dan prije spavanja od 1. do 42. dana svakog 42-dnevnog ciklusa. b Zbog sedacijskog učinka talidomida, primjena prije spavanja uglavnom poboljšava njegovu podnošljivost. c Doza melfalana primijenjena jedanput na dan od 1. do 4. dana svakog 42-dnevnog ciklusa. d Doziranje melfalana: smanjiti dozu za 50% kod umjerene (klirens kreatinina: ≥ 30 ali &lt; 50 ml/min) ili teške (CrCl: &lt; 30 ml/min) bubrežne insuficijencije. e Maksimalna dnevna doza melfalana: 24 mg (ispitanici u dobi ≤75 godina) ili 20 mg (ispitanici stariji od 75 godina). f Doza prednizona primijenjena jedanput na dan od 1. do 4. dana svakog 42-dnevnog ciklusa.
A titre of 1:80 was achieved in 84.2% of subjects aged 18-60 years and in 92.6% of subjects aged &gt; 60 years.
Titar od 1:80 postignut je u 84,2% ispitanika od 18 do 60 godina, te u 92,6% ispitanika starijih od 60 godina.
a To calculate the volume of injection (mL) for patients &lt; 60 kg, use the following formula: body weight (kg) x 0.0083 (mL/kg) or see Table 2.
a Za izračun volumena injekcije (ml) za bolesnike &lt; 60 kg, treba primijeniti sljedeću formulu: tjelesna težina (kg) x 0,0083 (ml/kg) ili vidjeti Tablicu 2.
A total of 1,006 patients with KPS≥60 were randomized to the following treatment groups:
Ukupno 1006 bolesnika s KPS &gt; 60 randomizirani su prema liječenju u sljedeće skupine:
A total of 1006 patients with KPS ≥ 60 were randomized to the following treatment groups:
Ukupno 1006 bolesnika s KPS &gt; 60 randomizirani su prema liječenju u sljedeće skupine:
A total of 1006 patients with KPS  60 were randomized to the following treatment groups:
Ukupno 1006 bolesnika s KPS &gt; 60 randomizirani su prema liječenju u sljedeće skupine:
A total of 152 children (1 month to &lt; 16 years of age) were treated with brivaracetam in a pharmacokinetic study and the related follow up study.
Ukupno je 152 djece (u dobi od 1 mjeseca do &lt; 16 godina) primalo brivaracetam u farmakokinetičkom ispitivanju i njegovu nastavnom ispitivanju.
A total of 180 subjects with alpha1-proteinase inhibitor deficiency characterized by a serum alpha1-proteinase inhibitor level &lt; 11 μM (i.e. &lt; 50 mg/dL as determined by nephelometry) and clinical evidence of emphysema, were randomized to receive a weekly 60 mg / kg bw intravenous dose of either Respreeza (93 subjects) or placebo (87 subjects) for up to 24 months.
Ukupno je 180 ispitanika s nedostatkom inhibitora alfa1-proteinaze s razinom inhibitora alfa1-proteinaze u serumu &lt; 11 μM (tj. &lt; 50 mg/dl određeno nefelometrijom) i kliničkim dokazima emfizema bilo randomizirano kako bi primali tjednu intravensku dozu od 60 mg/kg TT Respreeze (93 ispitanika) ili placebo (87 ispitanika) tijekom najviše 24 mjeseca.
A total of 195 subjects with severe haemophilia A (baseline factor VIII &lt; 1%) provided PK parameters that were included in the Per-Protocol PK analysis set.
Ukupno 195 ispitanika s teškom hemofilijom A (početna vrijednost faktora VIII &lt; 1%) dalo je farmakokinetičke parametre koji su uključeni u niz farmakokinetičkih analiza prema planu ispitivanja.
A total of 2532 patients (1286 Preotact and 1246 placebo), aged 45-94 years (8.1% 45-54 years and 11.4% &gt; 75 years), were randomised to receive 100 microgramsday or placebo with daily calcium (700 mg) and vitamin D (400 IU) supplementation.
Ukupno 2532 bolesnice (1.286 na Preotactu i 1.246 na placebu), u dobi 45-94 godina (8,1% 45-54 godina i 11,4%≥ 75 godina), randomizirane su u skupine gdje su primale 100 mikrograma/dan Preotacta ili placebo sa dnevnim dodatkom kalcija (700 mg) i vitamina D (400IJ).
A total of 259 (16%) of 1666 patients with at least 1 postbaseline vital sign assessment had a pulse rate &lt; 50 bpm.
Ukupno 259 (16%) od 1666 bolesnika s najmanje 1 procjenom vitalnih znakova nakon početka ispitivanja, imalo je srčanu frekvenciju &lt; 50 otkucaja u minuti.
A total of 29 major surgical procedures were performed and assessed in 19 subjects (17 adults, 1 adolescent and 1 paediatric patient &lt; 12 years of age) in study I and an extension study.
Ukupno je učinjeno i procijenjeno 29 većih kirurških zahvata u 19 ispitanika (17 odraslih, 1 adolescenta i 1 pedijatrijskog bolesnika &lt; 12 godina) u ispitivanju I i produžetku ispitivanja.
A total of 4,550 women (2,343 Prolia &amp; 2,207 placebo) who missed no more than one dose of investigational product in the pivotal study described above and completed the month 36 study visit agreed to enrol in a 7-year, multinational, multicentre, open-label, single-arm extension study to evaluate the long-term safety and efficacy of Prolia.
Ukupno 4550 žena (2343 Prolia i 2207 placebo) koje nisu propustile više od jedne doze ispitivanog lijeka u pivotalnom ispitivanju koje je opisano u prethodom tekstu i koje su završile posjet u 36. mjesecu studije pristalo je uključiti se u 7-godišnje, multinacionalno, multicentrično, otvoreno, produljeno ispitivanje na jednoj skupini kako bi se procijenila dugotrajna sigurnost primjene i djelotvornost lijeka Prolia.
A total of 5.8% of patients experienced an elevation of indirect bilirubin of &gt; 1 to 2 x ULN and 0.4% had an elevation of &gt; 2 x ULN.
Ukupno je 5,8% bolesnika imalo povećanje indirektnog bilirubina &gt; 1 do 2 puta iznad gornje granice normale, a 0,4% ih je imalo povećanje &gt; 2 puta iznad gornje granice normale.
A total of 54 (39.7%) patients received treatment for &gt; 12 months in the olaparib group compared with 14 (10.9%) patients in the placebo group.
Ukupno su 54 (39,7%) bolesnice u skupini liječenoj olaparibom primale liječenje tijekom &gt; 12 mjeseci, dok je isto zabilježeno u 14 (10,9%) bolesnica u skupini koja je primala placebo.
A total of 85 patients (15.2%) who started treatment at &lt; /= 500 mg (n= 558) received dose escalations to 600 mg of bosutinib.
Ukupno 85 bolesnika (15,2%) koji su započeli liječenje s &lt; /= 500 mg (n=558) primili su postupna povećanja doze do 600 mg bosutiniba.
A treatment effect was observed as early as 6 months, with Plegridy 125 micrograms every 2 weeks demonstrating a 61% reduction (p &lt; 0.0001) in new or newly enlarging T2 lesions as compared with placebo.
Učinak liječenja uočen je već nakon 6 mjeseci, pri čemu je primjena125 mikrograma Plegridyja svaka dva tjedna pokazala smanjenje od 61% (p &lt; 0,0001) novih ili novo povećanih T2 lezija u usporedbi s placebom.
a Treatment for patients with CrCl &lt; 30 ml/min is not recommended unless the benefits of Teysuno treatment clearly outweigh the risks.
a Ne preporučuje se liječenje bolesnika sa CrCl &lt; 30 ml/min osim ako korist liječenja lijekom Teysuno jasno premašuje rizike.
A trend to lower frequency of adverse reactions was associated with greater age; adults &gt; 65 years of age (regardless of prior pneumococcal vaccination status) reported fewer adverse reactions than younger adults, with adverse reactions generally most common in the youngest adults, 18 to 29 years of age.
Trend smanjivanja učestalosti nuspojava povezuje se s porastom dobi; odrasli &gt; 65 godina starosti (bez obzira na prethodni cjepni status protiv pneumokoka) prijavili su manje nuspojava nego mlađe odrasle osobe, a najčešće nuspojave općenito su se javile u najmlađih odraslih osoba, u dobi od 18 do 29 godina.
A Turkey 14/98, Asia1 Shamir and SAT2 Saudi Arabia
A Turkey 14/98, Asia1 Shamir &amp; SAT2 Saudi Arabia
A value &lt; 1 favours olaparib.
Vrijednost &lt; 1 ide u korist olapariba.
A weak to moderate complete membrane staining is detected in &gt; 10 % of the tumour cells.
Slaba do umjerena obojenost cijele membrane u &gt; 10 % tumorskih stanica.
A weak to moderate complete membrane staining is detected in &gt; 10 % of the tumour cells.
Slaba do umjerena obojenost cijele membrane u &gt; 10% tumorskih stanica.
A &amp; G Med Trading SRL Tel: +4021 332 49 91
A &amp; G Med Trading SRL Tel: + 4021 332 49 91
A22 Iraq, Asai1 Shamir and SAT2 Saudi Arabia
A22 Iraq, Asia1 Shamir &amp; SAT2 Saudi Arabia
A24 Cruzeiro and SAT2 Saudi Arabia
A Cruzeiro &amp; SAT2 Saudi Arabia
A24 Cruzeiro, Asia 1 Shamir and SAT2 Saudi Arabia
A24 Cruzeiro, Asia1 Shamir &amp; SAT2 Saudi Arabia
a: 25 mg Enbrel SC twice weekly b: p &lt; 0.001, Enbrel vs. placebo c: p &lt; 0.01, Enbrel vs. placebo
a: 25 mg Enbrela supkutano, dva puta tjedno b: p &lt; 0,001, Enbrel u odnosu na placebo c: p &lt; 0,01, Enbrel u odnosu na placebo
a: p &lt; 0.001, Enbrel vs. placebo
a: p &lt; 0,001, Enbrel u odnosu na Placebo
a: Treatment with concomitant TMZ can be continued when all of the following conditions are met: absolute neutrophil count ≥ 1.5 x 109/l; thrombocyte count ≥ 100 x 109/l; CTC non- haematological toxicity ≤ Grade 1 (except for alopecia, nausea, vomiting).
a: Istodobno liječenje temozolomidom može se nastaviti kada su zadovoljeni svi sljedeći uvjeti: apsolutni broj neutrofila &gt; 1,5 x 109/l; broj trombocita &gt; 100 x 109/l; nehematološka toksičnost prema CTC &lt; stupnju 1 (osim alopecije, mučnine i povraćanja).
aANC &lt; 0.5 x 109/l
aABN &lt; 0,5 x 109/l
aANC &lt; 0.5 x 109/L and/or platelets &lt; 10 x 109/L
aABN &lt; 0,5 x 109/l i/ili trombociti &lt; 10 x 109/l
Abbott Genostics solution hybridisation assay (LLOD &lt; 1.6 pg/ml
Abbott Genostics hibridizacijski test u otopini (LLOD &lt; 1,6 pg/ml)
Abbreviation: sPGA-static Physician Global Assessment p &lt; 0.0001 compared with placebo
Kratice: sPGA-statička opća procjena liječnika a. p &lt; 0,0001 u usporedbi s placebom
Abbreviation: sPGA-static Physician Global Assessment p &lt; 0.0001 compared with placebo
Kratice: sPGA-statička opća procjena liječnika p &lt; 0,0001 u usporedbi s placebom
Abbreviation: sPGA-static Physician Global Assessment. p &lt; 0.0001 compared with placebo.
Kratice: sPGA-statička opća procjena liječnika p &lt; 0,0001 u usporedbi s placebom
Abbreviations: CI = confidence interval; ITT = intent-to-treat; N = total population size a Statistically significant for noninferiority, with the entire confidence interval for HR well below the 1.17645 noninferiority margin (p &lt; 0.001)
Kratice: CI = interval pouzdanosti; ITT= populacija svih uključenih bolesnika; N = ukupan broj bolesnika. a Statistički značajan za neinferiornost, a cijeli interval pouzdanosti za HR nalazi se znatno ispod granice neinferiornosti od 1,17645 (p &lt; 0,001).
Abbreviations: CI = confidence interval; ITT = intent-to-treat; N = total population size. a Statistically significant for noninferiority, with the entire confidence interval for HR well below the 1.17645 noninferiority margin (p &lt; 0.001).
Kratice: CI = interval pouzdanosti; ITT = populacija svih uključenih bolesnika; n = ukupan broj bolesnika. a Statistički značajan za neinferiornost, a cijeli interval pouzdanosti za HR nalazi se znatno ispod granice neinferiornosti od 1,17645 (p &lt; 0,001).
Abbreviations: CI = confidence interval; ITT = intent-to-treat; N = total population size. a Statistically significant for noninferiority, with the entire confidence interval for HR well below the 1.17645 noninferiority margin (p &lt; 0.001).
Kratice: CI = interval pouzdanosti; ITT = populacija svih uključenih bolesnika; N = ukupan broj bolesnika. a Statistički značajan za neinferiornost, a cijeli interval pouzdanosti za HR nalazi se znatno ispod granice neinferiornosti od 1,17645 (p &lt; 0,001).
Abbreviations: CI = confidence interval; ITT = intent-to-treat; N = total population size. a Statistically significant for noninferiority, with the entire confidence interval for HR well below the 1.17645 noninferiority margin (p &lt; 0.001).
Kratice: CI = interval pouzdanosti; ITT = populacija uključenih bolesnika; N = ukupan broj bolesnika. a Statistički značajno za neinferiornost, cijeli interval pouzdanosti za HR znatno ispod granice neinferiornosti od 1,17645 (p &lt; 0,001).
Abbreviations: CI = confidence interval; ITT = intent-to-treat; N = total population size. aStatistically significant for noninferiority, with the entire confidence interval for HR well below the 1.17645 noninferiority margin (p &lt; 0.001).
Kratice: CI = interval pouzdanosti; ITT = populacija predviđena za liječenje; n = ukupna veličina populacije. a Statistički značajan za neinferiornost, s cijelim intervalom pouzdanosti za HR znatno ispod granice neinferiornosti od 1,17645 (p &lt; 0,001).
Abdominal pain
&lt; 1/100)
above normal &lt; baseline above normal &gt; baseline
više od normalnih &lt; početnih više od normalnih &gt; početnih
Abraxane is not recommended in patients that have total bilirubin &gt; 5 x ULN or AST &gt; 10 x ULN.
Abraxane se ne preporučuje u bolesnika u kojih je ukupni bilirubin &gt; 5 x GGN ili AST &gt; 10 x GGN.
Abraxane should not be administered until neutrophil counts recover to &gt; 1500 cells/mm3.
Abraxane se ne smije primjenjivati sve dok broj neutrofila ne poraste na &gt; 1500 stanica/mm3.
Absolute bioavailability is low ( &lt; 5% at the therapeutic oral dose) and the interindividual variability is substantial.
Apsolutna bioraspoloživost je niska ( &lt; 5% pri terapijskoj peroralnoj dozi) te je značajna interindividualna varijabilnost.
Absolute lymphocyte count &lt; 0.2x109/l, if confirmed, should lead to treatment interruption until recovery, because in clinical studies, fingolimod treatment was interrupted in patients with absolute lymphocyte count &lt; 0.2x109/l.
Ako se utvrdi apsolutni broj limfocita &lt; 0,2x109/l, terapiju je potrebno prekinuti do oporavka, budući da je i u kliničkim ispitivanjima terapija fingolimodom bila prekinuta u bolesnika s apsolutnim brojem limfocita &lt; 0,2x109/l.
absolute neutrophil count &lt; 1500/mm³ platelet count &lt; 100000/mm³
apsolutni broj neutrofila &lt; 1500/mm³ broj trombocita &lt; 100 000/mm³
Absolute neutrophil count &gt; 1500/microlitre
Apsolutni broj neutrofila &gt; 1500/mikrolitra
Absolute neutrophil count decreased ( &lt; 1,500/mm³) 
Smanjeni apsolutni broj neutrofila ( &lt; 1500/mm3) x
Absolute neutrophil count decreased ( &lt; 1,500/mm³) 
Smanjeni apsolutni broj neutrofila ( &lt; 1500/mm³)  
Absolute neutrophil count decreased ( &lt; 1500/mm³) 
Smanjeni apsolutni broj neutrofila ( &lt; 1500/mm³) 
Absorbed oseltamivir is primarily ( &gt; 90 %) eliminated by conversion to oseltamivir carboxylate.
0 %) eliminira pretvorbom u oseltamivirkarboksilat.
Absorbed oseltamivir is primarily ( &gt; 90 %) eliminated by conversion to oseltamivir carboxylate.
Apsorbirani oseltamivir uglavnom se ( &gt; 90 %) eliminira pretvorbom u oseltamivir karboksilat.
Absorbed oseltamivir is primarily ( &gt; 90 %) eliminated by conversion to oseltamivir carboxylate.
Apsorbirani oseltamivir uglavnom se ( &gt; 90 %) eliminira pretvorbom u oseltamivirkarboksilat.
Absorption: Nevirapine is readily absorbed ( &gt; 90 %) after oral administration in healthy volunteers and in adults with HIV-1 infection.
Apsorpcija: Nakon peroralne primjene nevirapin se dobro apsorbira ( &gt; 90%) u zdravih dobrovoljaca i odraslih s HIV-1 infekcijom.
Accelerated phase is defined by the presence of any of the following: blasts ≥ 15% but &lt; 30% in blood or bone marrow, blasts plus promyelocytes ≥ 30% in blood or bone marrow (providing &lt; 30% blasts), peripheral blood basophils ≥ 20%, platelets &lt; 100 x 109/l unrelated to therapy.
Ubrzana faza se definira prisutnošću bilo kojeg od sljedećih kriterija: blasti 15% ali &lt; 30% u krvi ili koštanoj srži, blasti plus promijelociti 30% u krvi ili koštanoj srži (što daje &lt; 30% blasta), bazofili u perifernoj krvi 20%, trombociti &lt; 100 x 109/l nevezano uz terapiju.
According to an independent review committee (IRC) assessment of patients with ALK-positive NSCLC (N=1669), 20 (1.2%) patients had ILD/pneumonitis, including 10 ( &lt; 1%) patients with fatal cases.
Prema ocjeni Nezavisnog odbora za procjenu bolesnika s ALK-pozitivnim NSCLC-om (N=1669), 20 (1,2%) bolesnika je imalo IBP/pneumonitis, uključujući 10 ( &lt; 1%) bolesnika sa smrtnim slučajem.
Achieved HIV RNA &lt; 50 copies/ml
Postigli &lt; 50 HIV-RNK kopija/ml
Achieved HIV RNA &lt; 50 copies/ml 54 % 57 %
Postigli &lt; 50 HIV-RNK kopija/ml 54% 57
Achieved ≥1 log10 HIV RNA drop from baseline or
Postigli smanjenje HIV-RNK za ≥ 1 log10 od početnih vrijednosti ili &lt; 400 kopija/ml
Aclasta is contraindicated in patients with creatinine clearance &lt; 35 ml/min (see sections 4.3 and 4.4).
Aclasta je kontraindicirana u bolesnika s klirensom kreatinina &lt; 35 ml/min (vidjeti djelove 4.3 and 4.4).
Aclasta significantly reduced the mean days of limited activity and the days of bed rest due to back pain by 17.9 days and 11.3 days respectively compared to placebo and significantly reduced the mean days of limited activity and the days of bed rest due to fractures by 2.9 days and 0.5 days respectively compared to placebo (all p &lt; 0.01).
Aclasta je značajno smanjila srednju vrijednost broja dana s ograničenom aktivnošću te dana provedenih u krevetu zbog boli u leđima za 17,9 dana, odnosno 11,3 dana u usporedbi s placebom te je značajno smanjila srednju vrijednost broja dana s ograničenom aktivnošću te dana provedenih u krevetu zbog prijeloma za 2,9 dana, odnosno 0,5 dana u usporedbi s placebom (za sve p &lt; 0,01).
Aclasta-treated patients aged 75 years and older exhibited a 60% reduction in the risk of vertebral fractures compared to placebo patients (p &lt; 0.0001).
Bolesnice liječene Aclastom u dobi od 75 godina i starije imale su 60%-tno smanjenje rizika za vertebralne prijelome u usporedbi s bolesnicama na placebu (p &lt; 0,0001).
Across all clinical studies, reports of changes in colour vision were rare ( &lt; 0.1 %).
U svim su kliničkim ispitivanjima izvješća o promjenama u raspoznavanju boja bila rijetka ( &lt; 0,1%).
Across all clinical studies, reports of changes in colour vision were rare ( &lt; 0.1%).
U svim su kliničkim ispitivanjima izvješća o promjenama u raspoznavanju boja bila rijetka ( &lt; 0,1 %).
Across monotherapy and combination mCRC clinical studies (n = 2,588), infusion-related reactions (occurring within 24 hours of an infusion) were reported in approximately 4% of Vectibix-treated patients, of which &lt; 1% were severe (NCI-CTC grade 3 and grade 4).
U kliničkim ispitivanjima monoterapije i kombiniranog liječenja mKRK-a (n = 2588), reakcije povezane s infuzijom (koje se javljaju unutar 24 sata od infuzije) prijavljene su u oko 4% bolesnika liječenih lijekom Vectibix, od kojih su &lt; 1% bile teške (NCI-CTC stupanj 3 i stupanj 4).
Across studies in patients with either ALK-positive or ROS1-positive NSCLC (N=1722), 50 (3%) patients treated with crizotinib had any grade all-causality ILD, including 18 (1%) patients with Grade 3 or 4, and 8 ( &lt; 1%) patients with fatal cases.
U ispitivanjima u bolesnika bilo s ALK-pozitivnim ili ROS1- pozitivnim NSCLC-om (N=1722), 50 (3%) bolesnika liječenih krizotinibom imalo je bilo koji stupanj IBP-a svih uzroka uključujući 18 (1%) bolesnika sa stupnjem 3 ili 4, te 8 ( &lt; 1%) bolesnika sa smrtnim slučajem.
ACT I and ACT III studied the effect of BRINAVESS in the treatment of patients with sustained atrial fibrillation &gt; 3 hours but not more than 45 days in duration.
U ispitivanjima ACT I i ACT III ispitivan je učinak lijeka BRINAVESS u liječenju bolesnika s produljenom fibrilacijom atrija koja je trajala &gt; 3 sata, ali ne dulje od 45 dana.
ACT II examined the effect of BRINAVESS on patients who developed atrial fibrillation of &lt; 3 days duration after recently undergoing coronary artery bypass graft, (CABG) and/or valvular surgery (atrial fibrillation occurred more than 1 day but less than 7 days after surgery).
U ispitivanju ACT II ispitivan je učinak lijeka BRINAVESS u bolesnika s fibrilacijom atrija u trajanju &lt; 3 dana koja se pojavila nedugo nakon ugradnje premosnice koronarnih arterija (CABG) i/ili kirurškog zahvata na zaliscima (fibrilacija atrija nastala više od jednog, ali manje od sedam dana nakon kirurškog zahvata).
actinic keratosis lesions were cleared. c Median percent (%) reduction in actinic keratosis lesions compared to baseline. d p &lt; 0.001; compared to vehicle by logistic regression with treatment, study and anatomical location.
početnog broja lezija aktiničke keratoze. c Medijan postotka (%) smanjenja lezija aktiničke keratoze u usporedbi s početnim vrijednostima. d p &lt; 0,001; u usporedbi s podlogom uz primjenu logističke regresije na liječenje, ispitivanje i anatomsku lokaciju.
Activating mutations in JAK2 (V617F or exon 12) are found in &gt; 95% of PV patients.
Aktivirajuće mutacije u JAK2 (V617F ili ekson 12) nalaze se u &gt; 95% bolesnika s PV-om.
Active substances:
Djelatna &lt; e &gt; tvar &lt; i &gt; :
acute bacterial endocarditis severe renal impairment defined by creatinine clearance &lt; 20 ml/min.
akutni bakterijski endokarditis teško oštećenje bubrega definirano kao klirens kreatinina &lt; 20 ml/min.
acute bacterial endocarditis severe renal impairment defined by creatinine clearance &lt; 30 ml/min.
akutni bakterijski endokarditis teško oštećenje bubrega definirano kao klirens kreatinina &lt; 30 ml/min.
Acute renal failure ( &lt; 1%) Renal failure ( &lt; 1%)
akutno zatajenje bubrega ( &lt; 1%) zatajenje bubrega ( &lt; 1%)
Acute stent thrombosis ( &lt; 24 hours) has been observed in patients with STEMI undergoing primary PCI and has been managed by Target Vessel Revascularisation (TVR) (see sections 4.8 and 5.1).
Akutna tromboza stenta ( &lt; 24 sati) opažena je u bolesnika sa STEMI-jem kod kojih je učinjena primarna PCI te je liječena je revaskularizacijom ciljne krvne žile (Target Vessel Revascularisation, TVR), (vidjeti dio 4.8 i 5.1).
Acute symptoms such as sweating, insomnia, tremor, anxiety, nausea, or vomiting have been reported rarely ( ≥ 0.01 % and &lt; 0.1 %) when olanzapine is stopped abruptly.
Akutni simptomi kao što su znojenje, nesanica, tremor, anksioznost, mučnina ili povraćanje rijetko su prijavljivani (≥ 0,01% i &lt; 0,1%) nakon naglog prekida uzimanja olanzapina.
Acute symptoms such as sweating, insomnia, tremor, anxiety, nausea, or vomiting have been reported rarely ( ≥ 0.01% and &lt; 0.1%) when olanzapine is stopped abruptly.
Akutni simptomi kao što su znojenje, nesanica, tremor, anksioznost, mučnina ili povraćanje rijetko su prijavljivani (≥ 0,01% i &lt; 0,1%) nakon naglog prekida uzimanja olanzapina.
Acute symptoms such as sweating, insomnia, tremor, anxiety, nausea, or vomiting have been reported rarely ( ≥0.01% and &lt; 0.1%) when olanzapine is stopped abruptly.
Akutni simptomi kao što su znojenje, nesanica, tremor, anksioznost, mučnina ili povraćanje rijetko su prijavljivani (≥ 0,01% i &lt; 0,1%) nakon naglog prekida uzimanja olanzapina.
Acute symptoms such as sweating, insomnia, tremor, anxiety, nausea, or vomiting have been reported rarely ( ≥0.01% and &lt; 0.1%)) when olanzapine is stopped abruptly.
Akutni simptomi kao što su znojenje, nesanica, tremor, anksioznost, mučnina ili povraćanje rijetko su prijavljivani (≥ 0,01% i &lt; 0,1%) nakon naglog prekida uzimanja olanzapina.
Acute symptoms such as sweating, insomnia, tremor, anxiety, nausea, or vomiting have been reported rarely (≥ 0.01 % and &lt; 0.1 %) when olanzapine is stopped abruptly.
Akutni simptomi kao što su znojenje, nesanica, tremor, anksioznost, mučnina ili povraćanje rijetko su prijavljivani (≥ 0,01% i &lt; 0,1%) nakon naglog prekida uzimanja olanzapina.
Acute symptoms such as sweating, insomnia, tremor, anxiety, nausea, or vomiting have been reported rarely (≥ 0.01% and &lt; 0.1% %) when olanzapine is stopped abruptly.
Akutni simptomi kao što su znojenje, nesanica, tremor, anksioznost, mučnina ili povraćanje vrlo su prijavljivani (≥ 0,01% i &lt; 0,1%) nakon naglog prekida uzimanja olanzapina.